Parmax Pharma Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported revenue from operations of INR 25.79 million. Profit from operations before exceptional items and tax was INR 3.69 million compared to loss from operations before exceptional items and tax of INR 0.034 million a year ago. Profit before tax was INR 0.37 million compared to loss before tax of INR 0.034 million a year ago. Profit for the period was INR 0.37 million or INR 0.10 per basic and diluted share compared to loss for the period of INR 0.034 million or INR 0.01 per basic and diluted share a year ago. For the nine months, the company reported revenue from operations of INR 87.42 million. Loss from operations before exceptional items and tax was INR 2.82 million compared to profit from operations before exceptional items and tax INR 0.017 million a year ago. Loss before tax was INR 2.82 million compared to profit before tax of INR 0.017 million a year ago. Loss for the period was INR 2.82 million or INR 0.75 per basic and diluted share compared to profit for the period of INR 0.017 million a year ago.